Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002865029 | SCV003627417 | uncertain significance | Inborn genetic diseases | 2022-06-10 | criteria provided, single submitter | clinical testing | The c.5005G>A (p.D1669N) alteration is located in exon 22 (coding exon 22) of the MED13L gene. This alteration results from a G to A substitution at nucleotide position 5005, causing the aspartic acid (D) at amino acid position 1669 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Department of Rehabilitation Medicine, |
RCV003319545 | SCV004023323 | pathogenic | Cardiac anomalies - developmental delay - facial dysmorphism syndrome | no assertion criteria provided | clinical testing |